More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$135957348
EPS
-2.32
P/E ratio
--
Price to sales
0.42
Dividend yield
--
Beta
0.652844
Previous close
$12
Today's open
$12.04
Day's range
$11.99 - $12.19
52 week range
$9.22 - $14.67
show more
CEO
Daniel R. Chard
Employees
504
Headquarters
Baltimore, MD
Exchange
New York Stock Exchange
Shares outstanding
11180703
Issue type
Common Stock
Consumer Discretionary
Personal Services
Can Medifast's New Compensation Plan Accelerate Coach Growth?
MED is reshaping its coach network around Executive Directors as productivity rises despite a sharp decline in active earning coaches.
Zacks Investment Research • Aug 21, 2026

Can Medifast's Coach Productivity Gains Help Revive Revenue Growth?
MED's improving coach productivity and client retention point to stabilization, but a shrinking coach base remains a challenge.
Zacks Investment Research • Aug 12, 2026

Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?
Medifast's Trilivy launch and cost cuts could support a Q4 profit turnaround, but shrinking revenue and its coach base keep risks high.
Zacks Investment Research • Aug 7, 2026

MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?
Medifast stock gains 13.6% in a month as improving coach productivity and earnings expectations support momentum despite weaker revenue.
Zacks Investment Research • Aug 7, 2026

Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?
Medifast's low valuation and improving coach productivity offer potential, but a shrinking coach base and weak growth keep the turnaround high risk.
Zacks Investment Research • Aug 7, 2026

Medifast: Worth A Speculative Entry As Sales Stabilize (Rating Upgrade)
Medifast, Inc. has started to report stabilizing sales through improved coach productivity, shown again in the Q2 report. Stabilized sales provide a pathway to stabilize earnings. MED targets profitability by Q4 already, but the target has to be taken with caution. Due to MED's $15.2 in net cash per share, the stock seems attractive. I estimate 44% upside to $18.8 on the condition that earnings improve near breakeven.
Seeking Alpha • Aug 6, 2026

Medifast Q2 Loss Narrower Than Expected, Coach Productivity Improves
MED tops Q2 earnings expectations despite lower sales, as rising coach productivity helps offset pressure from a shrinking coach network.
Zacks Investment Research • Aug 4, 2026

Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript
Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript
Seeking Alpha • Aug 4, 2026

Medifast Q2 Earnings Call Highlights
Medifast NYSE: MED reported second-quarter 2026 revenue of $76.4 million, down 27.6% from a year earlier, as its active earning coach base continued to decline amid the rapid adoption of GLP-1 medications across the traditional weight-loss category. The company posted a net loss of $3.1 million, or $0.28 per diluted share, compared with net income of $2.5 million, or $0.22 per share, in the prior-year quarter.
MarketBeat • Aug 4, 2026

Medifast Announces Second Quarter 2026 Financial Results
BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy, today reported results for the second quarter ended June 30, 2026. Second Quarter 2026 Revenue: $76.4 million, with revenue per active earning coach of $6,529 Independent active earning coaches of 11,700 Net loss of $3.1 million or $0.28 loss per diluted share ("EPS") Cash, Cash Equivalents, and Investment Securities of $169.8 million wit.
Business Wire • Aug 3, 2026

¹ Disclosures

Open an M1 investment account to buy and sell MEDIFAST INC commission-free¹. Build wealth for the long term using automated trading and transfers.